Medical Affairs 360
Medical Affairs 360 is a boutique medical advisory firm offering services to pharmaceutical and biotechnology companies. They provide Medical Affairs and Drug Safety expertise, supporting blockbuster pharmaceutical and biotechnology products for over 20 years. Their mission is to offer analysis, solutions, and expertise in the medical and scientific fields to their partner companies.
Industries
Nr. of Employees
small (1-50)
Products
Drug Safety Analytics and Pharmacovigilance
Provides analysis and monitoring of drug safety data to ensure the safety and efficacy of pharmaceutical products.
Drug Safety Analytics and Pharmacovigilance
Provides analysis and monitoring of drug safety data to ensure the safety and efficacy of pharmaceutical products.
Product Strategy
Offers strategic planning services to optimize the development and commercialization of pharmaceutical products.
Product Strategy
Offers strategic planning services to optimize the development and commercialization of pharmaceutical products.
Department Strategy and Processes
Assists in developing and refining strategies and processes for medical and scientific departments.
Department Strategy and Processes
Assists in developing and refining strategies and processes for medical and scientific departments.
Drug Safety Analytics and Pharmacovigilance
Provides analysis and monitoring of drug safety data to ensure the safety and efficacy of pharmaceutical products.
Drug Safety Analytics and Pharmacovigilance
Provides analysis and monitoring of drug safety data to ensure the safety and efficacy of pharmaceutical products.
Product Strategy
Offers strategic planning services to optimize the development and commercialization of pharmaceutical products.
Product Strategy
Offers strategic planning services to optimize the development and commercialization of pharmaceutical products.
Department Strategy and Processes
Assists in developing and refining strategies and processes for medical and scientific departments.
Department Strategy and Processes
Assists in developing and refining strategies and processes for medical and scientific departments.
Services
Advisory engagement to develop product positioning, lifecycle planning and commercialization strategy for pharmaceutical and biotechnology products.
Services to design and operate pharmacovigilance programs and perform safety data analytics to support risk assessment and reporting.
Consulting to develop departmental strategy, governance and process workflows for Medical Affairs and drug safety teams.
Advisory engagement to develop product positioning, lifecycle planning and commercialization strategy for pharmaceutical and biotechnology products.
Services to design and operate pharmacovigilance programs and perform safety data analytics to support risk assessment and reporting.
Consulting to develop departmental strategy, governance and process workflows for Medical Affairs and drug safety teams.
Expertise Areas
- Medical affairs advisory
- Pharmacovigilance and drug safety
- Product strategy and lifecycle management
- Department strategy and process optimization
Key Technologies
- Pharmacovigilance analytics
- Safety signal detection and assessment
- Medical/scientific writing and documentation
- Product strategy frameworks
News & Updates
Canada, the European Union, Japan, Mexico and South Korea will meet in Geneva to discuss how to respond to threats by U.S. President Donald Trump to impose tariffs on U.S. imports of autos and car parts.
Dana has reached an agreement to acquire Oerlikon’s drive systems business in a transaction valued at 600 million Swiss francs ($600 million). The business supplies high-precision gears and planetary hub drives for vehicles.
President Donald Trump has repeatedly lambasted the European Union over its high import tariffs and imbalanced auto trade, but in last week’s U.S.-EU agreement to discuss reducing tariffs on a wide range of goods, the auto sector was left out.
Researchers at York University’s Faculty of Health found that patients with metabolic healthy obesity, but no other metabolic risk factors, do not have an increased rate of mortality.
Canada, the European Union, Japan, Mexico and South Korea will meet in Geneva to discuss how to respond to threats by U.S. President Donald Trump to impose tariffs on U.S. imports of autos and car parts.
Dana has reached an agreement to acquire Oerlikon’s drive systems business in a transaction valued at 600 million Swiss francs ($600 million). The business supplies high-precision gears and planetary hub drives for vehicles.
President Donald Trump has repeatedly lambasted the European Union over its high import tariffs and imbalanced auto trade, but in last week’s U.S.-EU agreement to discuss reducing tariffs on a wide range of goods, the auto sector was left out.
Researchers at York University’s Faculty of Health found that patients with metabolic healthy obesity, but no other metabolic risk factors, do not have an increased rate of mortality.